AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations

Breast cancer was one of the first malignancies to benefit from targeted therapy, i.e., treatments directed against specific markers. Inhibitors against HER2 are a significant example and they improved the life expectancy of a large cohort of patients. Research on new biomarkers, therefore, is alway...

Descripción completa

Detalles Bibliográficos
Autores principales: Falcone, Italia, Conciatori, Fabiana, Bazzichetto, Chiara, Bria, Emilio, Carbognin, Luisa, Malaguti, Paola, Ferretti, Gianluigi, Cognetti, Francesco, Milella, Michele, Ciuffreda, Ludovica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696061/
https://www.ncbi.nlm.nih.gov/pubmed/33182542
http://dx.doi.org/10.3390/ijms21228419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696061/
https://www.ncbi.nlm.nih.gov/pubmed/33182542
http://dx.doi.org/10.3390/ijms21228419

Ejemplares similares